Cyclooxygenase (COX) Inhibitors and the Newborn Kidney
AbstractThis review summarizes our current understanding of the role of cyclo-oxygenase inhibitors (COXI) in influencing the structural development as well as the function of the developing kidney. COXI administered either during pregnancy or after birth can influence kidney development including nephronogenesis, and can decrease renal perfusion and ultrafiltration potentially leading to acute kidney injury in the newborn period. To date, which COX isoform (COX-1 or COX-2) plays a more important role in during fetal development and influences kidney function early in life is not known, though evidence points to a predominant role for COX-2. Clinical implications of the use of COXI in pregnancy and in the newborn infant are also evaluated herein, with specific reference to the potential effects of COXI on nephronogenesis as well as newborn kidney function. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Smith, F.G.; Wade, A.W.; Lewis, M.L.; Qi, W. Cyclooxygenase (COX) Inhibitors and the Newborn Kidney. Pharmaceuticals 2012, 5, 1160-1176.
Smith FG, Wade AW, Lewis ML, Qi W. Cyclooxygenase (COX) Inhibitors and the Newborn Kidney. Pharmaceuticals. 2012; 5(11):1160-1176.Chicago/Turabian Style
Smith, Francine G.; Wade, Andrew W.; Lewis, Megan L.; Qi, Wei. 2012. "Cyclooxygenase (COX) Inhibitors and the Newborn Kidney." Pharmaceuticals 5, no. 11: 1160-1176.